PL3455625T3 - Sposoby przewidywania przydatności neoantygenów w immunoterapii - Google Patents

Sposoby przewidywania przydatności neoantygenów w immunoterapii

Info

Publication number: PL3455625T3
Authority: PL; Poland
Prior art keywords: neoantigens; immunotherapy; predicting; usefulness; methods
Prior art date: 2016-05-13

Application number

PL17726208T

Other languages

English (en)

Inventor

Mathias VORMEHR

Ugur Sahin

Barbara SCHRÖRS

Martin LÖWER

Sebastian BOEGEL

Original Assignee

Biontech Rna Pharmaceuticals Gmbh

Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-13

Filing date

2017-05-10

Publication date

2021-01-25

2017-05-10 Application filed by Biontech Rna Pharmaceuticals Gmbh, Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh

2021-01-25 Publication of PL3455625T3 publication Critical patent/PL3455625T3/pl

Links

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Zoology (AREA)
Virology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

PL17726208T 2016-05-13 2017-05-10 Sposoby przewidywania przydatności neoantygenów w immunoterapii PL3455625T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/EP2016/060897 WO2017194170A1 (en)	2016-05-13	2016-05-13	Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
EP17726208.6A EP3455625B1 (en)	2016-05-13	2017-05-10	Methods for predicting the usefulness of neoantigens for immunotherapy
PCT/EP2017/061196 WO2017194610A1 (en)	2016-05-13	2017-05-10	Methods for predicting the usefulness of proteins or protein fragments for immunotherapy

Publications (1)

Publication Number	Publication Date
PL3455625T3 true PL3455625T3 (pl)	2021-01-25

Family

ID=55971007

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL20193183.9T PL3792628T3 (pl)	2016-05-13	2017-05-10	Sposoby przewidywania użyteczności neoantygenów do immunoterapii
PL17726208T PL3455625T3 (pl)	2016-05-13	2017-05-10	Sposoby przewidywania przydatności neoantygenów w immunoterapii

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL20193183.9T PL3792628T3 (pl)	2016-05-13	2017-05-10	Sposoby przewidywania użyteczności neoantygenów do immunoterapii

Country Status (27)

Country	Link
US (2)	US12153041B2 (pl)
EP (3)	EP3792628B1 (pl)
JP (5)	JP7529381B2 (pl)
KR (3)	KR20220020993A (pl)
CN (1)	CN109073637A (pl)
AU (2)	AU2017264546B2 (pl)
BR (1)	BR112018073221A2 (pl)
CA (1)	CA3022654A1 (pl)
CY (1)	CY1123520T1 (pl)
DK (2)	DK3792628T3 (pl)
ES (2)	ES2980781T3 (pl)
FI (1)	FI3792628T3 (pl)
HR (2)	HRP20201671T1 (pl)
HU (2)	HUE052240T2 (pl)
IL (2)	IL300841B1 (pl)
LT (2)	LT3792628T (pl)
MA (1)	MA43794B1 (pl)
MD (1)	MD3455625T2 (pl)
MX (2)	MX393653B (pl)
PL (2)	PL3792628T3 (pl)
PT (2)	PT3455625T (pl)
RS (2)	RS61071B1 (pl)
SG (1)	SG11201808495SA (pl)
SI (2)	SI3455625T1 (pl)
SM (2)	SMT202000622T1 (pl)
WO (2)	WO2017194170A1 (pl)
ZA (1)	ZA201805809B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102833333B1 (ko)	2016-01-08	2025-07-11	니코데 테라퓨틱스 에이에스에이	치료적 항암 네오에피토프 백신
WO2017194170A1 (en)	2016-05-13	2017-11-16	Biontech Rna Pharmaceuticals Gmbh	Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
EP3631471A4 (en)	2017-05-30	2021-06-30	Nant Holdings IP, LLC	Circulating tumor cell enrichment using neoepitopes
KR102267463B1 (ko) *	2018-02-15	2021-06-21	코쿠리츠다이가쿠호진 아사히카와 이카다이가쿠	암 항원 펩티드
US20220349010A1 (en)	2018-07-26	2022-11-03	Frame Pharmaceuticals B.V.	Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
IL280112B2 (en)	2018-07-26	2025-11-01	Curevac Netherlands B V	Cancer vaccines for breast cancer
CN109021062B (zh) *	2018-08-06	2021-08-20	倍而达药业（苏州）有限公司	一种肿瘤新抗原的筛选方法
CN111621564B (zh) *	2019-02-28	2022-03-25	武汉大学	一种鉴定有效肿瘤新抗原的方法
CA3132041A1 (en) *	2019-03-06	2020-09-10	Gritstone Bio, Inc.	Identification of neoantigens with mhc class ii model
CN110534156B (zh) *	2019-09-02	2022-06-17	深圳市新合生物医疗科技有限公司	一种提取免疫治疗新抗原的方法及系统
CN111487399B (zh) *	2020-03-26	2021-09-17	湖南师范大学	一种蛋白分子标记在鱼类生殖细胞发育研究中的应用
EP4392140A1 (en)	2021-08-24	2024-07-03	BioNTech SE	In vitro transcription technologies
WO2024083345A1 (en)	2022-10-21	2024-04-25	BioNTech SE	Methods and uses associated with liquid compositions
WO2025202937A1 (en)	2024-03-26	2025-10-02	BioNTech SE	Cancer vaccines

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2766205B1 (fr)	1997-07-16	2002-08-30	Inst Nat Sante Rech Med	Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1276896B1 (en) *	2000-04-28	2010-07-21	Mannkind Corporation	Epitope synchronization in antigen presenting cells
CA2415902A1 (en)	2000-07-10	2002-01-17	Xencor	Protein design automation for designing protein libraries with altered immunogenicity
ATE389668T1 (de) *	2000-07-31	2008-04-15	Greenpeptide Co Ltd	Tumorantigen
DE10225139A1 (de)	2002-05-29	2004-02-26	Immatics Biotechnologies Gmbh	Verfahren zur Identifizierung von immunreaktiven Peptiden
TW200418988A (en) *	2002-09-30	2004-10-01	Oncotherapy Science Inc	Method for diagnosing prostate cancer
CA2603191A1 (en) *	2005-03-29	2006-10-05	The Board Of Trustees Of The University Of Illinois	Cancer vaccines and therapeutic methods
JP2009273377A (ja) *	2008-05-12	2009-11-26	Igaku Seibutsugaku Kenkyusho:Kk	Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法
TW201000119A (en) *	2008-06-10	2010-01-01	Oncotherapy Science Inc	MYBL2 epitope peptides and vaccines containing the same
RS53782B1 (sr) *	2008-10-01	2015-06-30	Immatics Biotechnologies Gmbh	Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
US20120039806A1 (en)	2009-03-23	2012-02-16	Mireille Hanna Lahoud	Compounds and Methods for Modulating an Immune Response
WO2011050344A2 (en) *	2009-10-23	2011-04-28	Mannkind Corporation	Cancer immunotherapy and method of treatment
WO2012159643A1 (en)	2011-05-24	2012-11-29	Biontech Ag	Individualized vaccines for cancer
PL3892295T3 (pl)	2011-05-24	2023-07-24	BioNTech SE	Zindywidualizowane szczepionki przeciwnowotworowe
WO2012164004A1 (en) *	2011-06-01	2012-12-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Novel antigen peptide and uses thereof
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
KR102883915B1 (ko)	2015-12-16	2025-11-18	시애틀 프로젝트 코포레이션	신생항원 동정, 제조, 및 용도
WO2017194170A1 (en)	2016-05-13	2017-11-16	Biontech Rna Pharmaceuticals Gmbh	Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
EP3612965A4 (en)	2017-04-19	2021-01-13	Gritstone Oncology, Inc.	NEOANTIGEN IDENTIFICATION, MANUFACTURING AND USE
KR102729393B1 (ko)	2017-06-09	2024-11-13	그릿스톤 바이오, 인코포레이티드	신생항원 동정, 제조, 및 용도
WO2019050994A1 (en)	2017-09-05	2019-03-14	Gritstone Oncology, Inc.	IDENTIFICATION OF NEOANTIGEN FOR LYMPHOCYTE THERAPY T
WO2019075112A1 (en)	2017-10-10	2019-04-18	Gritstone Oncology, Inc.	IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20260008173A (ko)	2017-11-22	2026-01-15	시애틀 프로젝트 코포레이션	신생항원에 대한 접합 에피토프 제시 감소
IL276839B1 (en)	2018-02-27	2026-05-01	Gritstone Bio Inc	Neoantigen identification using pan-allelic models

2016
- 2016-05-13 WO PCT/EP2016/060897 patent/WO2017194170A1/en not_active Ceased
2017
- 2017-05-10 EP EP20193183.9A patent/EP3792628B1/en active Active
- 2017-05-10 DK DK20193183.9T patent/DK3792628T3/da active
- 2017-05-10 SM SM20200622T patent/SMT202000622T1/it unknown
- 2017-05-10 PT PT177262086T patent/PT3455625T/pt unknown
- 2017-05-10 HU HUE17726208A patent/HUE052240T2/hu unknown
- 2017-05-10 HR HRP20201671TT patent/HRP20201671T1/hr unknown
- 2017-05-10 SI SI201730466T patent/SI3455625T1/sl unknown
- 2017-05-10 LT LTEP20193183.9T patent/LT3792628T/lt unknown
- 2017-05-10 KR KR1020227002915A patent/KR20220020993A/ko not_active Ceased
- 2017-05-10 EP EP17726208.6A patent/EP3455625B1/en active Active
- 2017-05-10 EP EP24171718.0A patent/EP4411376A3/en active Pending
- 2017-05-10 ES ES20193183T patent/ES2980781T3/es active Active
- 2017-05-10 AU AU2017264546A patent/AU2017264546B2/en active Active
- 2017-05-10 MD MDE20190332T patent/MD3455625T2/ro unknown
- 2017-05-10 JP JP2018559794A patent/JP7529381B2/ja active Active
- 2017-05-10 DK DK17726208.6T patent/DK3455625T3/da active
- 2017-05-10 HR HRP20240704TT patent/HRP20240704T1/hr unknown
- 2017-05-10 MX MX2018013081A patent/MX393653B/es unknown
- 2017-05-10 CN CN201780026579.0A patent/CN109073637A/zh active Pending
- 2017-05-10 RS RS20201233A patent/RS61071B1/sr unknown
- 2017-05-10 HU HUE20193183A patent/HUE067497T2/hu unknown
- 2017-05-10 SI SI201731526T patent/SI3792628T1/sl unknown
- 2017-05-10 US US16/301,019 patent/US12153041B2/en active Active
- 2017-05-10 ES ES17726208T patent/ES2826480T3/es active Active
- 2017-05-10 KR KR1020187032652A patent/KR102358620B1/ko active Active
- 2017-05-10 BR BR112018073221-4A patent/BR112018073221A2/pt unknown
- 2017-05-10 SG SG11201808495SA patent/SG11201808495SA/en unknown
- 2017-05-10 PT PT201931839T patent/PT3792628T/pt unknown
- 2017-05-10 KR KR1020247031632A patent/KR20240146087A/ko active Pending
- 2017-05-10 PL PL20193183.9T patent/PL3792628T3/pl unknown
- 2017-05-10 WO PCT/EP2017/061196 patent/WO2017194610A1/en not_active Ceased
- 2017-05-10 CA CA3022654A patent/CA3022654A1/en active Pending
- 2017-05-10 RS RS20240614A patent/RS65568B1/sr unknown
- 2017-05-10 IL IL300841A patent/IL300841B1/en unknown
- 2017-05-10 PL PL17726208T patent/PL3455625T3/pl unknown
- 2017-05-10 MA MA43794A patent/MA43794B1/fr unknown
- 2017-05-10 FI FIEP20193183.9T patent/FI3792628T3/fi active
- 2017-05-10 LT LTEP17726208.6T patent/LT3455625T/lt unknown
- 2017-05-10 SM SM20240232T patent/SMT202400232T1/it unknown
2018
- 2018-08-29 ZA ZA2018/05809A patent/ZA201805809B/en unknown
- 2018-10-25 MX MX2022007902A patent/MX2022007902A/es unknown
- 2018-10-29 IL IL262680A patent/IL262680B2/en unknown
2020
- 2020-10-14 CY CY20201100969T patent/CY1123520T1/el unknown
2022
- 2022-02-16 JP JP2022021751A patent/JP2022081492A/ja active Pending
- 2022-07-27 AU AU2022209286A patent/AU2022209286A1/en active Pending
2024
- 2024-03-21 JP JP2024045130A patent/JP2024096712A/ja active Pending
- 2024-04-23 JP JP2024069742A patent/JP2024112805A/ja active Pending
- 2024-06-27 JP JP2024103724A patent/JP2024160216A/ja active Pending
- 2024-10-18 US US18/920,525 patent/US20250244311A1/en active Pending

Also Published As

Publication number	Publication date
DK3792628T3 (da)	2024-06-17
DK3455625T3 (da)	2020-10-26
RU2018137721A (ru)	2020-06-15
CA3022654A1 (en)	2017-11-16
HRP20240704T1 (hr)	2024-09-27
AU2022209286A1 (en)	2022-08-25
EP3455625B1 (en)	2020-09-02
JP2024112805A (ja)	2024-08-21
EP3792628B1 (en)	2024-04-24
EP4411376A2 (en)	2024-08-07
KR102358620B1 (ko)	2022-02-07
EP4411376A3 (en)	2025-03-19
US20250244311A1 (en)	2025-07-31
SMT202000622T1 (it)	2021-01-05
HRP20201671T1 (hr)	2021-03-05
EP3455625A1 (en)	2019-03-20
KR20240146087A (ko)	2024-10-07
IL262680B1 (en)	2023-04-01
HUE052240T2 (hu)	2021-04-28
RS61071B1 (sr)	2020-12-31
BR112018073221A2 (pt)	2019-02-19
US12153041B2 (en)	2024-11-26
WO2017194170A1 (en)	2017-11-16
KR20220020993A (ko)	2022-02-21
JP2024160216A (ja)	2024-11-13
IL262680A (en)	2018-12-31
CN109073637A (zh)	2018-12-21
SI3792628T1 (sl)	2024-08-30
ZA201805809B (en)	2020-12-23
MD3455625T2 (ro)	2020-12-31
ES2826480T3 (es)	2021-05-18
MA43794B1 (fr)	2020-12-31
ES2980781T3 (es)	2024-10-03
IL300841B1 (en)	2026-05-01
JP2024096712A (ja)	2024-07-17
EP3792628A2 (en)	2021-03-17
IL300841A (en)	2023-04-01
AU2017264546A1 (en)	2018-10-18
WO2017194610A1 (en)	2017-11-16
EP3792628A3 (en)	2021-05-19
LT3792628T (lt)	2024-06-25
IL262680B2 (en)	2023-08-01
SMT202400232T1 (it)	2024-07-09
JP2019520554A (ja)	2019-07-18
CY1123520T1 (el)	2022-03-24
MX2022007902A (es)	2022-07-21
LT3455625T (lt)	2021-01-11
PT3455625T (pt)	2020-10-22
KR20190008218A (ko)	2019-01-23
MX393653B (es)	2025-03-24
MA43794A (fr)	2019-03-20
JP7529381B2 (ja)	2024-08-06
HUE067497T2 (hu)	2024-10-28
RS65568B1 (sr)	2024-06-28
PT3792628T (pt)	2024-06-18
JP2022081492A (ja)	2022-05-31
FI3792628T3 (fi)	2024-06-07
PL3792628T3 (pl)	2024-07-15
MX2018013081A (es)	2019-01-24
SG11201808495SA (en)	2018-10-30
RU2018137721A3 (pl)	2020-08-25
AU2017264546B2 (en)	2022-04-28
SI3455625T1 (sl)	2021-01-29
US20190178871A1 (en)	2019-06-13

Publication	Publication Date	Title
PT3792628T (pt)	2024-06-18	Métodos para prever a utilidade de neoantigénios para imunoterapia
GB2527164B (en)	2018-08-15	Apparatus, kits and methods for the prediction of onset of sepsis
EP3198010A4 (en)	2018-06-06	Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
GB201511191D0 (en)	2015-08-12	T-cell epitopes for the immunotherapy of myeloma
IL271031A (en)	2020-01-30	Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
EP3107566A4 (en)	2017-10-11	Biomarker directed multi-target immunotherapy
EP3158330A4 (en)	2018-01-17	Apparatuses and methods for determining analyte charge
SG10202007893TA (en)	2020-10-29	Methods of immunotherapy
EP3129781A4 (en)	2017-10-11	Protein biomarkers for immune assessment and prediction of transplant rejection
EP3484525A4 (en)	2020-07-29	MULTIVIRUS-SPECIFIC T-LYMPHOCYTES IMMUNOTHERAPY
IL263517B (en)	2022-10-01	Gamma-glutamyl-l-epsilon-lysine-specific monoclonal antibody for monitoring apoptosis
EP3189330A4 (en)	2018-03-28	Solid support for improved detection of interaction between species
EP3092005A4 (en)	2017-08-02	Antibodies against glioma biomarkers
SG11202106249QA (en)	2021-07-29	Methods for improved immunotherapy
ZA201708254B (en)	2019-07-31	Biomarkers for detection of tuberculosis risk
GB201520524D0 (en)	2016-01-06	Apparatus and methods of using of biomarkers for predicting tnf-inhibitor response
EP3138923A4 (en)	2018-01-03	Method for predicting prognosis of acute myeloid leukemia relapse
AU2017275640A1 (en)	2018-10-25	Biomarkers for predicting degree of weight loss
HK40008959A (en)	2020-06-19	Anti-idiotypic antibodies against anti-cd19 antibodies
HK40002299A (en)	2020-03-20	Modified cells for immunotherapy
HUP1400447A2 (hu)	2016-03-29	Fehérje multimerek specifikus detektálására alkalmas szendvics-ELISA egymással kompetálható antitestek használatával